up-to-date with a click!
Update May, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications May 2018

Add on treatments

  1. Kirhmajer MV, Sarinic VM, Simicevic L et al. Rosuvastatin-induced rhabdomyolysis - Possible role of ticagrelor and patients' Pharmacogenetic profile. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29734517
  2. Wang Y, Kuang ZM, Feng SJ et al. Combined antihypertensive and statin therapy for the prevention of cardiovascular events in patients with hypertension without complications: protocol for a systematic review and meta-analysis. BMJ Open 2018; 8:e019719. http://www.ncbi.nlm.nih.gov/pubmed/?term=29858408
  3. Kim W, Yoon YE, Shin SH et al. Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29857919
  4. Oh M, Ghim JL, Park SE et al. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects. Drug design, development and therapy 2018; 12:1157-1164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29780236
  5. Hong N, Lee YH, Tsujita K et al. Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. Endocrinol Metab (Seoul) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29766679
  6. Liu C, Liu Q, Xiao X. Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease. Experimental and therapeutic medicine 2018; 15:4683-4688. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805487
  7. Ito Y, Maejima Y, Tamura N et al. Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure. FEBS open bio 2018; 8:799-816. http://www.ncbi.nlm.nih.gov/pubmed/?term=29744294
  8. Leite GAA, Figueiredo TM, Guerra MT et al. Ascorbic acid co-administered with rosuvastatin reduces reproductive impairment in the male offspring from male rats exposed to the statin at pre-puberty. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29778496
  9. Ageev FT, Blankova ZN, Samsonova NS. [The effect of changing of conventional antihypertensive therapy to a triple fixed combination therapy with rosuvastatin in high cardiovascular risk patients]. Kardiologiia 2018:46-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=29782289
  10. VanWagner LB. Aspirin and Statin Use for Management of Atherosclerotic Cardiovascular Disease in Liver Transplant Candidates: Are We Missing the Mark? Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29781097
  11. Quon J, Parkin L, Sharples K, Barson D. Co-prescribing of contraindicated and use-with-caution drugs in a national cohort of new users of simvastatin: how well are prescribing guidelines followed? The New Zealand medical journal 2018; 131:35-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723177
  12. Kaleem Z, Khan JA, Mushtaq Z et al. Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. Pak J Pharm Sci 2018; 31:801-806. http://www.ncbi.nlm.nih.gov/pubmed/?term=29716858
  13. Bartlett LE, Pratt NL, Roughead EE. Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts. Patient preference and adherence 2018; 12:835-843. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805251
  14. Gonzalez-Juanatey JR. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg. Rev Esp Cardiol (Engl Ed) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29752030
  15. Auer J, Berent R. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Ther Adv Cardiovasc Dis 2018:1753944718775352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29792380

Adherence

  1. Thakkar J, Redfern J, Khan E et al. Healthcare resource utilisation by patients with coronary heart disease receiving a lifestyle-focused text message support program: an analysis from the TEXT ME study. Australian journal of primary health 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29789100
  2. Ju A, Hanson CS, Banks E et al. Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract 2018. https://www.ncbi.nlm.nih.gov/pubmed/29784867
  3. Murai K, Sakata K, Mabuchi T et al. Very late bare metal stent thrombosis in the setting of discontinuation of optimal medical therapy for 2 years. Cardiovascular diagnosis and therapy 2018; 8:186-189. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850411
  4. Brinton EA. Understanding Patient Adherence and Concerns with STatins and MedicatION Discussions with Physicians (ACTION): A Survey on the Patient Perspective of Dialogue with Healthcare Providers Regarding Statin Therapy. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29749101
  5. Liu H, Zhang M, Li D et al. Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound: a meta-analysis. Coronary artery disease 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29738341
  6. Khan S, Holbrook A, Shah BR. Does Googling lead to statin intolerance? Int J Cardiol 2018; 262:25-27. http://www.ncbi.nlm.nih.gov/pubmed/?term=29706390
  7. Tobert JA. Statins - Good drugs, not so good reputation. Int J Cardiol 2018; 262:28-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29706391
  8. Booth JN, 3rd, Colantonio LD, Rosenson RS et al. Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29739799
  9. Dao N, Lee S, Hata M, Sarino L. Impact of Appointment-Based Medication Synchronization on Proportion of Days Covered for Chronic Medications. Pharmacy (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29786638

Atherosclerosis & Imaging

  1. Roberts WC. Quantitative Extent of Atherosclerotic Plaque in the Major Epicardial Coronary Arteries in Patients with Fatal Coronary Heart Disease, in Coronary Endarterectomy Specimens, in Aorta-Coronary Saphenous Venous Conduits, and Means to Prevent the Plaques: A Review after Studying the Coronary Arteries for 50 Years. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29753395
  2. Murai K, Sakata K, Mabuchi T et al. Very late bare metal stent thrombosis in the setting of discontinuation of optimal medical therapy for 2 years. Cardiovascular diagnosis and therapy 2018; 8:186-189. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850411
  3. Corsini A, Pacini D, Lovato L et al. Long-term Follow up of Patients with Acute Aortic Syndromes: Relevance of both Aortic and Non-aortic Events. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779910
  4. Liu Y, Chen T, Xing J. Effect of rosuvastatin on the expression of candidate gene GALNT3 in atherosclerosis. Experimental and therapeutic medicine 2018; 15:4880-4884. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805509
  5. Konishi T, Funayama N, Yamamoto T et al. Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29789903
  6. Spanos K, Tzorbatzoglou I, Lazari P et al. Carotid artery plaque echomorphology and its association with histopathologic characteristics. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29803682
  7. Wang L, Lin R, Guo L, Hong M. Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPARgamma and UCP2. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29845235
  8. Chen X, Wang S, Lin L et al. Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis. Pak J Pharm Sci 2018; 31:1169-1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29737302
  9. Andrews J, Psaltis PJ, Bartolo BAD et al. Coronary arterial calcification: A review of mechanisms, promoters and imaging. Trends Cardiovasc Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29753636
  10. Texakalidis P, Giannopoulos S, Kokkinidis DG et al. Outcome of Carotid Artery Endarterectomy in Statin-users versus Statin-naive patients: A Systematic Review and Meta-analysis. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29859356

Atorvastatin/Rosuvastatin

  1. Syam Das S, Nair SS, Indira M. Atorvastatin modulates drug transporters and ameliorates nicotine-induced testicular toxicity. Andrologia 2018:e13029. http://www.ncbi.nlm.nih.gov/pubmed/?term=29740849
  2. Zheng D, Cai A, Xu R et al. Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia. Archives of medical science : AMS 2018; 14:629-634. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765452
  3. Colombo M, Looker HC, Farran B et al. Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis 2018; 274:182-190. http://www.ncbi.nlm.nih.gov/pubmed/?term=29793175
  4. Kirhmajer MV, Sarinic VM, Simicevic L et al. Rosuvastatin-induced rhabdomyolysis - Possible role of ticagrelor and patients' Pharmacogenetic profile. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29734517
  5. Bhadoriya A, Sanyal M, Shah PA, Shrivastav PS. Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. Biomedical chromatography : BMC 2018:e4291. http://www.ncbi.nlm.nih.gov/pubmed/?term=29782035
  6. Wang YZ, Yang L, Li CF. Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 104:240-251. http://www.ncbi.nlm.nih.gov/pubmed/?term=29775891
  7. Hjelmesaeth J, Asberg A, Andersson S et al. Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). BMJ Open 2018; 8:e021878. http://www.ncbi.nlm.nih.gov/pubmed/?term=29844102
  8. Lee H, Choi JM, Cho JY et al. Regulation of Endogenic Metabolites by Rosuvastatin in Hyperlipidemia Patients: An Integration of Metabolomics and Lipidomics. Chemistry and physics of lipids 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29852124
  9. Hesami O, Sistanizad M, Asadollahzade E et al. Comparing the Effects of Atorvastatin With Sodium Valproate (Divalproex) on Frequency and Intensity of Frequent Migraine Headaches: A Double-blind Randomized Controlled Study. Clinical neuropharmacology 2018; 41:94-97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29746282
  10. Kim W, Yoon YE, Shin SH et al. Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29857919
  11. Liu H, Zhang M, Li D et al. Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound: a meta-analysis. Coronary artery disease 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29738341
  12. Awad K, Banach M. The optimal time of day for statin administration: a review of current evidence. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771699
  13. Oh M, Ghim JL, Park SE et al. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects. Drug design, development and therapy 2018; 12:1157-1164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29780236
  14. Liu C, Liu Q, Xiao X. Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease. Experimental and therapeutic medicine 2018; 15:4683-4688. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805487
  15. Liu Y, Chen T, Xing J. Effect of rosuvastatin on the expression of candidate gene GALNT3 in atherosclerosis. Experimental and therapeutic medicine 2018; 15:4880-4884. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805509
  16. Leite GAA, Figueiredo TM, Guerra MT et al. Ascorbic acid co-administered with rosuvastatin reduces reproductive impairment in the male offspring from male rats exposed to the statin at pre-puberty. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29778496
  17. Cai L, Bai X, Lei H et al. High Plasma Exposure of Statins Associated With Increased Risk of Contrast-Induced Acute Kidney Injury in Chinese Patients With Coronary Artery Disease. Frontiers in pharmacology 2018; 9:427. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760658
  18. Calza L, Colangeli V, Borderi M et al. Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia. HIV clinical trials 2018; 19:120-128. http://www.ncbi.nlm.nih.gov/pubmed/?term=29770749
  19. Fujisue K, Shirakawa T, Nakamura S et al. Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases - INVITATION trial. J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735336
  20. Lin J, Banathy A, Winters C et al. Achieving Guideline-Driven High-Intensity Statin Dose in Cardiac Rehabilitation Patients With Coronary Artery Disease. Journal of cardiopulmonary rehabilitation and prevention 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29762264
  21. Barter PJ, Waters DD. Variations in time to benefit among clinical trials of cholesterol-lowering drugs. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779997
  22. da Silva KLC, Camacho AP, Mittestainer FC et al. Atorvastatin and diacerein reduce insulin resistance and increase disease tolerance in rats with sepsis. Journal of inflammation (London, England) 2018; 15:8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760586
  23. Dalugama C, Pathirage M, Kularatne SAM. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. Journal of medical case reports 2018; 12:143. http://www.ncbi.nlm.nih.gov/pubmed/?term=29784023
  24. Ageev FT, Blankova ZN, Samsonova NS. [The effect of changing of conventional antihypertensive therapy to a triple fixed combination therapy with rosuvastatin in high cardiovascular risk patients]. Kardiologiia 2018:46-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=29782289
  25. Basyoni MMA, Fouad SA, Amer MF et al. Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy. The Korean journal of parasitology 2018; 56:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29742864
  26. Bae SH, Park WS, Han S et al. Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2018; 22:321-329. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719454
  27. Jin Z, Jung Y, Yi CO et al. Atorvastatin pretreatment attenuates kainic acid-induced hippocampal neuronal death via regulation of lipocalin-2-associated neuroinflammation. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2018; 22:301-309. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719452
  28. Jiang LY, Jiang YH, Qi YZ et al. Integrated analysis of long noncoding RNA and mRNA profiling ox-LDL-induced endothelial dysfunction after atorvastatin administration. Medicine (Baltimore) 2018; 97:e10949. http://www.ncbi.nlm.nih.gov/pubmed/?term=29851839
  29. Han J, Yin QH, Fang Y et al. Atorvastatin protects BV2 mouse microglia and hippocampal neurons against oxygenglucose deprivationinduced neuronal inflammatory injury by suppressing the TLR4/TRAF6/NFkappaB pathway. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29845194
  30. Wang L, Lin R, Guo L, Hong M. Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPARgamma and UCP2. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29845235
  31. Reklou A, Doumas M, Imprialos K et al. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? The open cardiovascular medicine journal 2018; 12:29-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785212
  32. Spreider PA, Breit B. Palladium-Catalyzed Stereoselective Cyclization of in Situ Formed Allenyl Hemiacetals: Synthesis of Rosuvastatin and Pitavastatin. Organic letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771125
  33. Araujo-Lima CF, Christoni LSA, Justo G et al. Atorvastatin Downregulates In Vitro Methyl Methanesulfonate and Cyclophosphamide Alkylation-Mediated Cellular and DNA Injuries. Oxidative medicine and cellular longevity 2018; 2018:7820890. http://www.ncbi.nlm.nih.gov/pubmed/?term=29849914
  34. Chen X, Wang S, Lin L et al. Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis. Pak J Pharm Sci 2018; 31:1169-1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29737302
  35. Gonzalez-Juanatey JR. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg. Rev Esp Cardiol (Engl Ed) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29752030
  36. Zheng W, Yang W, Zhang QE et al. Meta-analysis of the Efficacy and Safety of Adjunctive Rosuvastatin for Dyslipidemia in Patients with Schizophrenia. Shanghai archives of psychiatry 2018; 30:4-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719353
  37. Zhou ZY, Huang B, Li S et al. Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish. Toxicology and applied pharmacology 2018; 350:32-42. http://www.ncbi.nlm.nih.gov/pubmed/?term=29730311
  38. Holl DC, Volovici V, Dirven CMF et al. Pathophysiology and non-surgical treatment of chronic subdural hematoma: from past to present to future. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29772364
  39. Li Y, Zhao SP, Li Y. [Periprocedural high-dose statin strategy shown no benefits on clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary interventions]. Zhonghua xin xue guan bing za zhi 2018; 46:338-340. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804433

Basic science

  1. AlSwafeeri H, ElKenany W, Mowafy M, Karam S. Effect of local administration of simvastatin on postorthodontic relapse in a rabbit model. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2018; 153:861-871. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853244
  2. Dolci GS, Ballarini A, Gameiro GH et al. Atorvastatin inhibits osteoclastogenesis and arrests tooth movement. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2018; 153:872-882. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853245
  3. Syam Das S, Nair SS, Indira M. Atorvastatin modulates drug transporters and ameliorates nicotine-induced testicular toxicity. Andrologia 2018:e13029. http://www.ncbi.nlm.nih.gov/pubmed/?term=29740849
  4. Ridruejo E, Romero-Caimi G, Obregon MJ et al. Potential Molecular Targets of Statins in the Prevention of Hepatocarcinogenesis. Annals of hepatology 2018; 17:490-500. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735800
  5. Zheng D, Cai A, Xu R et al. Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia. Archives of medical science : AMS 2018; 14:629-634. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765452
  6. Yu SM, Kim SJ. Kruppel-like factor 4 (KLF-4) plays a crucial role in simvastatin (SVT)-induced differentiation of rabbit articular chondrocytes. Biochem Biophys Res Commun 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29775609
  7. Bhadoriya A, Sanyal M, Shah PA, Shrivastav PS. Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. Biomedical chromatography : BMC 2018:e4291. http://www.ncbi.nlm.nih.gov/pubmed/?term=29782035
  8. Wang YZ, Yang L, Li CF. Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 104:240-251. http://www.ncbi.nlm.nih.gov/pubmed/?term=29775891
  9. Yorulmaz H, Ozkok E, Kaptan E et al. Therapeutic Effects of Simvastatin on Galectin-3, and Oxidative Stress parameters in Lung Tissue in Endotoxemia. Bioscience reports 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853535
  10. Lee H, Choi JM, Cho JY et al. Regulation of Endogenic Metabolites by Rosuvastatin in Hyperlipidemia Patients: An Integration of Metabolomics and Lipidomics. Chemistry and physics of lipids 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29852124
  11. Li X, Wu F, Zhang Y et al. Discontinuation of simvastatin leads to a rebound phenomenon and results in immediate peri-implant bone loss. Clinical and experimental dental research 2016; 2:65-72. http://www.ncbi.nlm.nih.gov/pubmed/?term=29744151
  12. Eskinazi-Budge A, Manickavasagam D, Czech T et al. Preparation of Emulsifying Wax/GMO Nanoparticles and Evaluation as a Delivery System for Repurposing Simvastatin in Bone Regeneration. Drug development and industrial pharmacy 2018:1-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=29847182
  13. de Bruyn T, Ufuk A, Cantrill C et al. Predicting Human Clearance of OATP substrates using Cynomolgus monkey: In vitro-in vivo scaling of hepatic uptake clearance. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29720472
  14. Yao Y, Toshimoto K, Kim SJ et al. Quantitative analysis of complex drug-drug interactions (DDIs) between cerivastatin and inhibitors using physiologically based pharmacokinetic (PBPK) modeling. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29712725
  15. Kato S, Liberona MF, Cerda-Infante J et al. Simvastatin interferes with cancer 'stem-cell' plasticity reducing metastasis in ovarian cancer. Endocrine-related cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29848667
  16. Matera MG, Calzetta L, Gritti G et al. Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. Eur J Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29782855
  17. Zhang M, Bian YQ, Tao HM et al. Simvastatin induces osteogenic differentiation of MSCs via Wnt/beta-catenin pathway to promote fracture healing. Eur Rev Med Pharmacol Sci 2018; 22:2896-2905. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771446
  18. Hu X, Song C, Fang M, Li C. Erratum: Simvastatin inhibits the apoptosis of hippocampal cells in a mouse model of Alzheimer's disease. Experimental and therapeutic medicine 2018; 15:5153. http://www.ncbi.nlm.nih.gov/pubmed/?term=29809201
  19. Liu Y, Chen T, Xing J. Effect of rosuvastatin on the expression of candidate gene GALNT3 in atherosclerosis. Experimental and therapeutic medicine 2018; 15:4880-4884. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805509
  20. Rocha KCE, Pereira BMV, Rodrigues AC. An update on efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29842801
  21. Ito Y, Maejima Y, Tamura N et al. Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure. FEBS open bio 2018; 8:799-816. http://www.ncbi.nlm.nih.gov/pubmed/?term=29744294
  22. Chen T, Wang Y, Zhang T et al. Simvastatin Enhances Activity and Trafficking of alpha7 Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways. Frontiers in pharmacology 2018; 9:362. http://www.ncbi.nlm.nih.gov/pubmed/?term=29706890
  23. Kong B, Wang X, Yang W et al. Effects of simvastatin on the function of splenic CD4(+) and CD8(+) T cells in sepsis mice. Immunologic research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29752615
  24. Lee H, Lee H, Na CB, Park JB. Effects of Simvastatin on the Viability and Secretion of Vascular Endothelial Growth Factor of Cell Spheroids Cultured in Growth Media. Implant dentistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29846274
  25. Nabi R, Alvi SS, Khan R et al. Antiglycation study of HMG-R inhibitors and tocotrienol against glycated BSA and LDL: A comparative study. International journal of biological macromolecules 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29782986
  26. Zhang JY, Bai QK, Zhang YD. Pretreatment with simvastatin upregulates expression of BK-2R and CD11b in the ischemic penumbra of rats. Journal of biomedical research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29784898
  27. Liu L, Cheeti S, Yoshida K et al. Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects. Journal of clinical pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29786857
  28. da Silva KLC, Camacho AP, Mittestainer FC et al. Atorvastatin and diacerein reduce insulin resistance and increase disease tolerance in rats with sepsis. Journal of inflammation (London, England) 2018; 15:8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760586
  29. Di Donna L, Bartella L, Napoli A et al. Assay of lovastatin containing dietary supplement by LC-MS/MS under MRM condition. Journal of mass spectrometry : JMS 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29770527
  30. Basyoni MMA, Fouad SA, Amer MF et al. Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy. The Korean journal of parasitology 2018; 56:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29742864
  31. Jin Z, Jung Y, Yi CO et al. Atorvastatin pretreatment attenuates kainic acid-induced hippocampal neuronal death via regulation of lipocalin-2-associated neuroinflammation. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2018; 22:301-309. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719452
  32. Ugwu DI, Okoro UC, Mishra NK, Okafor SN. Novel Phenoxazinones as potent agonist of PPAR-alpha: design, synthesis, molecular docking and in vivo studies. Lipids Health Dis 2018; 17:120. http://www.ncbi.nlm.nih.gov/pubmed/?term=29789011
  33. Shrivastava-Ranjan P, Flint M, Bergeron E et al. Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing. mBio 2018; 9. http://www.ncbi.nlm.nih.gov/pubmed/?term=29717011
  34. Thompson JM, Alvarez A, Singha MK et al. Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through a HIF-dependent mechanism. Molecular cancer therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29720560
  35. Han J, Yin QH, Fang Y et al. Atorvastatin protects BV2 mouse microglia and hippocampal neurons against oxygenglucose deprivationinduced neuronal inflammatory injury by suppressing the TLR4/TRAF6/NFkappaB pathway. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29845194
  36. Wang L, Lin R, Guo L, Hong M. Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPARgamma and UCP2. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29845235
  37. Iizuka-Ohashi M, Watanabe M, Sukeno M et al. Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells. Oncotarget 2018; 9:19597-19612. http://www.ncbi.nlm.nih.gov/pubmed/?term=29731968
  38. Ogura S, Yoshida Y, Kurahashi T et al. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget 2018; 9:21022-21035. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765517
  39. Spreider PA, Breit B. Palladium-Catalyzed Stereoselective Cyclization of in Situ Formed Allenyl Hemiacetals: Synthesis of Rosuvastatin and Pitavastatin. Organic letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771125
  40. Araujo-Lima CF, Christoni LSA, Justo G et al. Atorvastatin Downregulates In Vitro Methyl Methanesulfonate and Cyclophosphamide Alkylation-Mediated Cellular and DNA Injuries. Oxidative medicine and cellular longevity 2018; 2018:7820890. http://www.ncbi.nlm.nih.gov/pubmed/?term=29849914
  41. Hamidreza Kheiri M, Alimohammadi N, Danafar H. Preparation of biocompatible copolymeric micelles as a carrier of atorvastatin and rosuvastatin for potential anticancer activity study. Pharmaceutical development and technology 2018:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=29741465
  42. Yang Y, Wang J, He H et al. Influence of Fatty Acid Modification on Uptake of Lovastatin-Loaded Reconstituted High Density Lipoprotein by Foam Cells. Pharm Res 2018; 35:134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29736804
  43. Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLoS One 2018; 13:e0197422. http://www.ncbi.nlm.nih.gov/pubmed/?term=29763460
  44. Carson RA, Rudine AC, Tally SJ et al. Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms. PLoS One 2018; 13:e0196387. http://www.ncbi.nlm.nih.gov/pubmed/?term=29738536
  45. Zhou ZY, Huang B, Li S et al. Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish. Toxicology and applied pharmacology 2018; 350:32-42. http://www.ncbi.nlm.nih.gov/pubmed/?term=29730311
  46. Chang JH, Zhang X, Messick K et al. Unremarkable Impact of Oatp Inhibition on the Liver Concentration of Fluvastatin, Lovastatin and Pitavastatin in Wild-Type and Oatp1a/1b Knockout Mouse. Xenobiotica 2018:1-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=29768081
  47. Zhang K, Liu G, Tian F, Zhang L. Regulatory Effect of Simvastatin On Middle/L ate Stages Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells Via p38MAPK Pathway. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 2016; 30:1038-1043. http://www.ncbi.nlm.nih.gov/pubmed/?term=29786238

Cancer

  1. Ridruejo E, Romero-Caimi G, Obregon MJ et al. Potential Molecular Targets of Statins in the Prevention of Hepatocarcinogenesis. Annals of hepatology 2018; 17:490-500. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735800
  2. Oh TK, Kim K, Jheon S et al. Impact of Statin Use on Recurrence or Survival After Surgical Curative Resection of Non-Small Cell Lung Cancer. Cancer control : journal of the Moffitt Cancer Center 2018; 25:1073274818778000. http://www.ncbi.nlm.nih.gov/pubmed/?term=29781295
  3. Kato S, Liberona MF, Cerda-Infante J et al. Simvastatin interferes with cancer 'stem-cell' plasticity reducing metastasis in ovarian cancer. Endocrine-related cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29848667
  4. Kim YS, Park MS, Lee JH et al. Effect of Statins on Survival Following Stroke in Patients With Cancer. Frontiers in neurology 2018; 9:205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29740381
  5. Boland AJ, Gangadharan N, Kavanagh P et al. Simvastatin Suppresses Interleukin Ibeta Release in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418776261. http://www.ncbi.nlm.nih.gov/pubmed/?term=29764192
  6. Thompson JM, Alvarez A, Singha MK et al. Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through a HIF-dependent mechanism. Molecular cancer therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29720560
  7. Gordon JA, Buonerba C, Pond G et al. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget 2018; 9:19861-19873. http://www.ncbi.nlm.nih.gov/pubmed/?term=29731989
  8. Ogura S, Yoshida Y, Kurahashi T et al. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget 2018; 9:21022-21035. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765517
  9. Hamidreza Kheiri M, Alimohammadi N, Danafar H. Preparation of biocompatible copolymeric micelles as a carrier of atorvastatin and rosuvastatin for potential anticancer activity study. Pharmaceutical development and technology 2018:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=29741465
  10. Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLoS One 2018; 13:e0197422. http://www.ncbi.nlm.nih.gov/pubmed/?term=29763460
  11. Allott EH, Farnan L, Steck SE et al. Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC. Prostate 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29717502
 

Children

  1. King K, Macken A, Blake O, O'Gorman CS. Cholesterol screening and statin use in children: a literature review. Irish journal of medical science 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29858795

Cost-effectiveness

  1. Kumar R, Tonkin A, Liew D, Zomer E. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29731350
  2. Ngo-Metzger Q, Zuvekas SH, Bierman AS. Estimated Impact of US Preventive Services Task Force Recommendations on Use and Cost of Statins for Cardiovascular Disease Prevention. Journal of general internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29855861
  3. Korman MJ, Retterstol K, Kristiansen IS, Wisloff T. Are PCSK9 Inhibitors Cost Effective? PharmacoEconomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29777433

CVD

  1. Nakamura Y, Asaumi Y, Miyagi T et al. Comparison of Long-Term Mortality in Patients With Previous Coronary Artery Bypass Grafting Who Underwent Percutaneous Coronary Intervention With Versus Without Optimal Medical Therapy. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29747859
  2. Ma B, Sun J, Diao S et al. Effects of perioperative statins on patient outcomes after noncardiac surgery: a meta-analysis. Annals of medicine 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29741972
  3. Humphries SE, Cooper JA, Seed M et al. Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. Atherosclerosis 2018; 274:41-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=29751283
  4. Karlson BW, Nicholls SJ, Lundman P et al. Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. Cardiology 2018; 140:30-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=29705799
  5. Barter PJ. High- Versus Low-Dose Statin: Effects on Cardiovascular Events and All-Cause Death. Circulation 2018; 137:2013-2015. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735589
  6. Devereaux PJ. Suboptimal Outcome of Myocardial Infarction After Noncardiac Surgery: Physicians Can and Should Do More. Circulation 2018; 137:2340-2343. http://www.ncbi.nlm.nih.gov/pubmed/?term=29844070
  7. Taguchi I, Iimuro S, Iwata H et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation 2018; 137:1997-2009. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735587
  8. Kim S, Kim H, Kim E et al. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-Based Study in South Korea. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735297
  9. Ito Y, Maejima Y, Tamura N et al. Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure. FEBS open bio 2018; 8:799-816. http://www.ncbi.nlm.nih.gov/pubmed/?term=29744294
  10. Nichols GA, Philip S, Reynolds K et al. Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850861
  11. Kim BS, Yang JH, Jang WJ et al. Long-term Survival Benefit of Statin in Patients with Coronary Chronic Total Occlusion without Revascularization. J Korean Med Sci 2018; 33:e134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29713254
  12. Anroedh SS, Hilvo M, Akkerhuis KM et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29858423
  13. Song PS, Ryu DR, Kim MJ et al. Risk Scoring System to Assess Outcomes in Patients Treated with Contemporary Guideline-Adherent Optimal Therapies after Acute Myocardial Infarction. Korean Circ J 2018; 48:492-504. http://www.ncbi.nlm.nih.gov/pubmed/?term=29856143
  14. Le Bras A. Genetic variation explains residual CHD risk with statin therapy. Nat Rev Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29777181
  15. Li Y, Zhao SP, Li Y. [Periprocedural high-dose statin strategy shown no benefits on clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary interventions]. Zhonghua xin xue guan bing za zhi 2018; 46(5): 338-340. https://www.ncbi.nlm.nih.gov/pubmed/29804433

Endothelium/inflammation

  1. Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual Inflammatory Risk On Treatment with PCSK9 Inhibition and Statin Therapy. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29716940
  2. Lee H, Lee H, Na CB, Park JB. Effects of Simvastatin on the Viability and Secretion of Vascular Endothelial Growth Factor of Cell Spheroids Cultured in Growth Media. Implant dentistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29846274
  3. Cainzos-Achirica M, Miedema MD, McEvoy JW et al. The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after >10years of follow-up: The Multi-Ethnic Study of Atherosclerosis (MESA). Int J Cardiol 2018; 264:158-164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29776564
  4. Fujisue K, Shirakawa T, Nakamura S et al. Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases - INVITATION trial. J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735336
  5. Boland AJ, Gangadharan N, Kavanagh P et al. Simvastatin Suppresses Interleukin Ibeta Release in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418776261. http://www.ncbi.nlm.nih.gov/pubmed/?term=29764192
  6. Reklou A, Doumas M, Imprialos K et al. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? The open cardiovascular medicine journal 2018; 12:29-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785212
  7. Clarke R, Valdes-Marquez E, Hill M et al. Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. Open heart 2018; 5:e000807. http://www.ncbi.nlm.nih.gov/pubmed/?term=29713486

Ethnicity

  1. Cartolano FC, Pappiani C, Freitas MCP et al. Is Lipid Accumulation Product Associated with an Atherogenic Lipoprotein Profile in Brazilian Subjects? Arquivos brasileiros de cardiologia 2018; 110:339-347. http://www.ncbi.nlm.nih.gov/pubmed/?term=29791572
  2. Harewood-Marshall AS, Craig LS, Martelly TP et al. Managing acute ischaemic stroke in a small island developing state: meeting the guidelines in Barbados. BMC public health 2018; 18:648. http://www.ncbi.nlm.nih.gov/pubmed/?term=29788951
  3. Teramoto T. Extending the "Lower is Better" Principle to Japanese and Possibly Other Asian Populations. Circulation 2018; 137:2010-2012. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735588
  4. Kim S, Kim H, Kim E et al. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-Based Study in South Korea. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735297
  5. Danchin N, Almahmeed W, Al-Rasadi K et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018:2047487318777079. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771156
  6. Zhang X, Jing J, Zhao X et al. Statin Use during Hospitalization and Short-Term Mortality in Acute Ischaemic Stroke with Chronic Kidney Disease. European neurology 2018; 79:296-302. http://www.ncbi.nlm.nih.gov/pubmed/?term=29852478
  7. Cai L, Bai X, Lei H et al. High Plasma Exposure of Statins Associated With Increased Risk of Contrast-Induced Acute Kidney Injury in Chinese Patients With Coronary Artery Disease. Frontiers in pharmacology 2018; 9:427. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760658
  8. Yamashita S, Masuda D, Arai H, Matsuzawa Y. Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29780067
  9. Cano-Corres R, Candas-Estebanez B, Padro-Miquel A et al. Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia. Journal of clinical laboratory analysis 2018:e22566. http://www.ncbi.nlm.nih.gov/pubmed/?term=29732606
  10. Dalugama C, Pathirage M, Kularatne SAM. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. Journal of medical case reports 2018; 12:143. http://www.ncbi.nlm.nih.gov/pubmed/?term=29784023
  11. Li H, Lin H, Zhao H et al. Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People's Republic of China. Therapeutics and clinical risk management 2018; 14:823-832. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765224

FH

  1. Humphries SE, Cooper JA, Seed M et al. Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. Atherosclerosis 2018; 274:41-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=29751283
  2. Weng S, Kai J, Tranter J et al. Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study. Atherosclerosis 2018; 274:54-60. http://www.ncbi.nlm.nih.gov/pubmed/?term=29751285
  3. Virani SS, Kennedy KF, Akeroyd JM et al. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol >/=190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes 2018; 11:e004652. http://www.ncbi.nlm.nih.gov/pubmed/?term=29748356
  4. Yamashita S, Masuda D, Arai H, Matsuzawa Y. Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29780067
  5. Agirbasli D, Hyatt T, Agirbasli M. Familial hypercholesterolemia with extensive coronary artery disease and tuberous and tendinous xanthomas: A case report and mutation analysis. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29784571
  6. Aljenedil S, Ruel I, Watters K, Genest J. Severe xanthomatosis in heterozygous familial hypercholesterolemia. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=2977856

Genetics

  1. Ross S, Gerstein H, Pare G. The Genetic Link Between Diabetes and Atherosclerosis. Can J Cardiol 2018; 34:565-574. http://www.ncbi.nlm.nih.gov/pubmed/?term=29731020
  2. Cano-Corres R, Candas-Estebanez B, Padro-Miquel A et al. Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia. Journal of clinical laboratory analysis 2018:e22566. http://www.ncbi.nlm.nih.gov/pubmed/?term=29732606
  3. Jiang LY, Jiang YH, Qi YZ et al. Integrated analysis of long noncoding RNA and mRNA profiling ox-LDL-induced endothelial dysfunction after atorvastatin administration. Medicine (Baltimore) 2018; 97:e10949. http://www.ncbi.nlm.nih.gov/pubmed/?term=29851839
  4. Le Bras A. Genetic variation explains residual CHD risk with statin therapy. Nat Rev Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29777181
  5. Gryn SE, Kim RB. Personalized medicine: importance of clinical interpretative skills for real-world patient care. Personalized medicine 2014; 11:395-408. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783478
  6. Luzum JA, Luzum MJ. Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Personalized medicine 2016; 13:119-127. http://www.ncbi.nlm.nih.gov/pubmed/?term=29749904
  7. Molokhia M, Bhatia S, Nitsch D. Genetic determinants of statin-associated myopathy. Personalized medicine 2008; 5:481-494. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783452
  8. Wilke RA. Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection. Personalized medicine 2006; 3:385-390. http://www.ncbi.nlm.nih.gov/pubmed/?term=29788593

Guidelines

  1. Yebyo HG, Aschmann HE, Yu T, Puhan MA. Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts. BMC Cardiovasc Disord 2018; 18:97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29776337
  2. Harewood-Marshall AS, Craig LS, Martelly TP et al. Managing acute ischaemic stroke in a small island developing state: meeting the guidelines in Barbados. BMC public health 2018; 18:648. http://www.ncbi.nlm.nih.gov/pubmed/?term=29788951
  3. Lin J, Banathy A, Winters C et al. Achieving Guideline-Driven High-Intensity Statin Dose in Cardiac Rehabilitation Patients With Coronary Artery Disease. Journal of cardiopulmonary rehabilitation and prevention 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29762264
  4. Egan BM, Li J, Davis RA et al. Differences in primary cardiovascular disease prevention between the 2013 and 2016 cholesterol guidelines and impact of the 2017 hypertension guideline in the United States. Journal of clinical hypertension (Greenwich, Conn.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29774988
  5. Lamprecht DG, Jr., Shaw PB, King JB et al. Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29803357
  6. Ngo-Metzger Q, Zuvekas SH, Bierman AS. Estimated Impact of US Preventive Services Task Force Recommendations on Use and Cost of Statins for Cardiovascular Disease Prevention. Journal of general internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29855861
  7. Song PS, Ryu DR, Kim MJ et al. Risk Scoring System to Assess Outcomes in Patients Treated with Contemporary Guideline-Adherent Optimal Therapies after Acute Myocardial Infarction. Korean Circ J 2018; 48:492-504. http://www.ncbi.nlm.nih.gov/pubmed/?term=29856143
  8. Gonzalez-Juanatey JR. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg. Rev Esp Cardiol (Engl Ed) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29752030

LDL- related parameters

  1. Cartolano FC, Pappiani C, Freitas MCP et al. Is Lipid Accumulation Product Associated with an Atherogenic Lipoprotein Profile in Brazilian Subjects? Arquivos brasileiros de cardiologia 2018; 110:339-347. http://www.ncbi.nlm.nih.gov/pubmed/?term=29791572
  2. Weng S, Kai J, Tranter J et al. Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study. Atherosclerosis 2018; 274:54-60. http://www.ncbi.nlm.nih.gov/pubmed/?term=29751285
  3. Danchin N, Almahmeed W, Al-Rasadi K et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018:2047487318777079. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771156
  4. Alter DA, Tu JV, Koh M et al. Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29754125
  5. Kuller LH. Reducing Low-Density Lipoprotein Cholesterol After Myocardial Infarction in Older Individuals, Levels Versus Change: Can Observational Studies Answer the Questions? J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29754126
  6. Burkholder GA, Muntner P, Zhao H et al. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853312
  7. Lamprecht DG, Jr., Shaw PB, King JB et al. Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29803357
  8. Anroedh SS, Hilvo M, Akkerhuis KM et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29858423
  9. Bandyopadhyay D, Qureshi A, Ghosh S et al. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management. Journal of lipids 2018; 2018:8598054. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850255
  10. Reklou A, Doumas M, Imprialos K et al. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? The open cardiovascular medicine journal 2018; 12:29-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785212

Lifestyle

  1. Maksymets T, Karpyshyn N, Gutor T et al. Influence of risk factors on insulin resistance in patients with overweight and obesity. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2018; 71:558-560. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783224

Meta-analyses

  1. Ma B, Sun J, Diao S et al. Effects of perioperative statins on patient outcomes after noncardiac surgery: a meta-analysis. Annals of medicine 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29741972
  2. Wang Y, Kuang ZM, Feng SJ et al. Combined antihypertensive and statin therapy for the prevention of cardiovascular events in patients with hypertension without complications: protocol for a systematic review and meta-analysis. BMJ Open 2018; 8:e019719. http://www.ncbi.nlm.nih.gov/pubmed/?term=29858408
  3. Liu H, Zhang M, Li D et al. Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound: a meta-analysis. Coronary artery disease 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29738341
  4. Hong N, Lee YH, Tsujita K et al. Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. Endocrinol Metab (Seoul) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29766679
  5. Barter PJ, Waters DD. Variations in time to benefit among clinical trials of cholesterol-lowering drugs. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779997
  6. Cui JY, Zhou RR, Han S et al. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. Journal of clinical pharmacy and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29733433
  7. Zheng W, Yang W, Zhang QE et al. Meta-analysis of the Efficacy and Safety of Adjunctive Rosuvastatin for Dyslipidemia in Patients with Schizophrenia. Shanghai archives of psychiatry 2018; 30:4-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719353
  8. Texakalidis P, Giannopoulos S, Kokkinidis DG et al. Outcome of Carotid Artery Endarterectomy in Statin-users versus Statin-naive patients: A Systematic Review and Meta-analysis. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29859356

Metabolic Syndrome - Diabetes

  1. Colombo M, Looker HC, Farran B et al. Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis 2018; 274:182-190. http://www.ncbi.nlm.nih.gov/pubmed/?term=29793175
  2. Kim S, Kim H, Kim E et al. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-Based Study in South Korea. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735297
  3. Ginsberg HN, Farnier M, Robinson JG et al. Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779195
  4. Athyros VG, Doumas M, Imprialos KP et al. Diabetes and lipid metabolism. Hormones (Athens, Greece) 2018; 17:61-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29858856
  5. Cui JY, Zhou RR, Han S et al. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. Journal of clinical pharmacy and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29733433
  6. da Silva KLC, Camacho AP, Mittestainer FC et al. Atorvastatin and diacerein reduce insulin resistance and increase disease tolerance in rats with sepsis. Journal of inflammation (London, England) 2018; 15:8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760586
  7. Elbadawi-Sidhu M, Baillie RA, Zhu H et al. Pharmacometabolomic signature links simvastatin therapy and insulin resistance. Metabolomics : open access 2017; 13. http://www.ncbi.nlm.nih.gov/pubmed/?term=29732238
  8. Andrade Lopes S, Fumani C, Jornayvaz FR et al. [Dyslipidemia management in patients with type 1 diabetes]. Revue medicale suisse 2018; 14:1118-1122. http://www.ncbi.nlm.nih.gov/pubmed/?term=29851318
  9. Li H, Lin H, Zhao H et al. Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People's Republic of China. Therapeutics and clinical risk management 2018; 14:823-832. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765224
  10. Maksymets T, Karpyshyn N, Gutor T et al. Influence of risk factors on insulin resistance in patients with overweight and obesity. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2018; 71:558-560. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783224

New Treatments

  1. Bandyopadhyay D, Qureshi A, Ghosh S et al. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management. Journal of lipids 2018; 2018:8598054. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850255
  2. Auer J, Berent R. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Ther Adv Cardiovasc Dis 2018:1753944718775352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29792380
  3. Ginsberg HN, Farnier M, Robinson JG et al. Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779195
  4. Korman MJ, Retterstol K, Kristiansen IS, Wisloff T. Are PCSK9 Inhibitors Cost Effective? PharmacoEconomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29777433
  5. Bandyopadhyay D, Ashish K, Hajra A et al. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. Journal of lipids 2018; 2018:3179201. http://www.ncbi.nlm.nih.gov/pubmed/?term=29770231
  6. Liberale L, Carbone F, Bertolotto M et al. Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. Int J Cardiol 2018; 263:138-141. http://www.ncbi.nlm.nih.gov/pubmed/?term=29754909
  7. Lin XL, Xiao LL, Tang ZH et al. Role of PCSK9 in lipid metabolism and atherosclerosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 104:36-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29758414
  8. Weisshaar S, Zeitlinger M. Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia? Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29737499
  9. Ray KK, Stoekenbroek RM, Kallend D et al. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735484
  10. Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual Inflammatory Risk On Treatment with PCSK9 Inhibition and Statin Therapy. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29716940

Other

  1. Jaspers NEM, Visseren FLJ, Numans ME et al. Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives. BMJ Open 2018; 8:e021309. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804065
  2. Gryn SE, Kim RB. Personalized medicine: importance of clinical interpretative skills for real-world patient care. Personalized medicine 2014; 11:395-408. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783478
  3. VanWagner LB. Aspirin and Statin Use for Management of Atherosclerotic Cardiovascular Disease in Liver Transplant Candidates: Are We Missing the Mark? Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29781097
  4. Yamashita S, Masuda D, Arai H, Matsuzawa Y. Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29780067
  5. Awad K, Banach M. The optimal time of day for statin administration: a review of current evidence. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771699
  6. Yebyo HG, Aschmann HE, Yu T, Puhan MA. Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts. BMC Cardiovasc Disord 2018; 18:97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29776337

PAD and statins

  1. Thiney M, Della Schiava N, Ecochard R et al. Effects on mortality and cardiovascular events of adherence to guideline-recommended therapy 4 years after lower extremity arterial revascularization. Annals of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29777848

Pleiotropic effects of statins

  1. Policardo L, Seghieri G, Gualdani E, Franconi F. Effect of statins in preventing hospitalizations for infections: A population study. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29808503
  2. Han J, Yin QH, Fang Y et al. Atorvastatin protects BV2 mouse microglia and hippocampal neurons against oxygenglucose deprivationinduced neuronal inflammatory injury by suppressing the TLR4/TRAF6/NFkappaB pathway. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29845194
  3. Degala S, Bathija NA. Evaluation of the Efficacy of Simvastatin in Bone Regeneration after Surgical Removal of Bilaterally Impacted Third Molars-A Split-Mouth Randomized Clinical Trial. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29859160
  4. Waugh N, Loveman E, Colquitt J et al. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Health technology assessment (Winchester, England) 2018; 22:1-168. http://www.ncbi.nlm.nih.gov/pubmed/?term=29846169
  5. Rocha KCE, Pereira BMV, Rodrigues AC. An update on efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29842801
  6. Kato S, Liberona MF, Cerda-Infante J et al. Simvastatin interferes with cancer 'stem-cell' plasticity reducing metastasis in ovarian cancer. Endocrine-related cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29848667
  7. Yorulmaz H, Ozkok E, Kaptan E et al. Therapeutic Effects of Simvastatin on Galectin-3, and Oxidative Stress parameters in Lung Tissue in Endotoxemia. Bioscience reports 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853535
  8. Tran PT, Meeker AK, Platz EA. Association between statin drug use and peripheral blood leukocyte telomere length in the National Health and Nutrition Examination Survey 1999-2002: a cross-sectional study. Annals of epidemiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853162
  9. Zhang K, Liu G, Tian F, Zhang L. [REGUL ATORY EFFECT OF SIMVASTATIN ON MIDDLE/L ATE STAGES OSTEOGENIC DIFFERENTIATION OF BONE MARROW MESENCHYMAL STEM CELLS VIA p38MAPK PATHWAY]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 2016; 30:1038-1043. http://www.ncbi.nlm.nih.gov/pubmed/?term=29786238
  10. Maillart E. Treatment of progressive multiple sclerosis: Challenges and promising perspectives. Revue neurologique 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779852
  11. Reklou A, Doumas M, Imprialos K et al. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? The open cardiovascular medicine journal 2018; 12:29-40. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785212
  12. da Silva KLC, Camacho AP, Mittestainer FC et al. Atorvastatin and diacerein reduce insulin resistance and increase disease tolerance in rats with sepsis. Journal of inflammation (London, England) 2018; 15:8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760586
  13. Magan-Fernandez A, Rizzo M, Montalto G, Marchesini G. Statins in liver disease: not only prevention of cardiovascular events. Expert Rev Gastroenterol Hepatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29768950
  14. Wang YZ, Yang L, Li CF. Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 104:240-251. http://www.ncbi.nlm.nih.gov/pubmed/?term=29775891
  15. Park JS, Kim BW, Hong TJ et al. Lower In-Hospital Ventricular Tachyarrhythmia in Patients With Acute Myocardial Infarction Receiving Prior Statin Therapy. Angiology 2018:3319718775902. http://www.ncbi.nlm.nih.gov/pubmed/?term=29758993
  16. Paraskevas KI. Letter to the Editor: Effect of Statin Therapy on Survival After Abdominal Aortic Aneurysm Repair: A Systematic Review and Meta-analysis. World journal of surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29750322
  17. Piechota-Polanczyk A, Kopacz A, Kloska D et al. Simvastatin Treatment Upregulates HO-1 in Patients with Abdominal Aortic Aneurysm but Independently of Nrf2. Oxidative medicine and cellular longevity 2018; 2018:2028936. http://www.ncbi.nlm.nih.gov/pubmed/?term=29743974
  18. Basyoni MMA, Fouad SA, Amer MF et al. Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy. The Korean journal of parasitology 2018; 56:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29742864
  19. Kong B, Wang X, Yang W et al. Effects of simvastatin on the function of splenic CD4(+) and CD8(+) T cells in sepsis mice. Immunologic research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29752615
  20. Balaguer C, Peralta A, Rios A et al. Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. Contemporary clinical trials communications 2016; 2:91-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=29736450
  21. Hesami O, Sistanizad M, Asadollahzade E et al. Comparing the Effects of Atorvastatin With Sodium Valproate (Divalproex) on Frequency and Intensity of Frequent Migraine Headaches: A Double-blind Randomized Controlled Study. Clinical neuropharmacology 2018; 41:94-97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29746282
  22. Li X, Wu F, Zhang Y et al. Discontinuation of simvastatin leads to a rebound phenomenon and results in immediate peri-implant bone loss. Clinical and experimental dental research 2016; 2:65-72. http://www.ncbi.nlm.nih.gov/pubmed/?term=29744151
  23. Ridruejo E, Romero-Caimi G, Obregon MJ et al. Potential Molecular Targets of Statins in the Prevention of Hepatocarcinogenesis. Annals of hepatology 2018; 17:490-500. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735800
  24. Lin TK, Chou P, Lin CH et al. Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study. PLoS One 2018; 13:e0196713. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723231
  25. Shrivastava-Ranjan P, Flint M, Bergeron E et al. Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing. mBio 2018; 9. http://www.ncbi.nlm.nih.gov/pubmed/?term=29717011
  26. Chen T, Wang Y, Zhang T et al. Simvastatin Enhances Activity and Trafficking of alpha7 Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways. Frontiers in pharmacology 2018; 9:362. http://www.ncbi.nlm.nih.gov/pubmed/?term=29706890
  27. Elwan N, Salah R, Hamisa M et al. Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial. F1000Research 2018; 7:256. http://www.ncbi.nlm.nih.gov/pubmed/?term=29707200
  28. Lin HW, Ho YF, Lin FJ. Statin Use Associated with Lower Risk of Epilepsy after Intracranial Hemorrhage: A Population-Based Cohort Study. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29714813

Primary Prevention

  1. Egan BM, Li J, Davis RA et al. Differences in primary cardiovascular disease prevention between the 2013 and 2016 cholesterol guidelines and impact of the 2017 hypertension guideline in the United States. Journal of clinical hypertension (Greenwich, Conn.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29774988
  2. Ebell MH, Grad R. Top 20 Research Studies of 2017 for Primary Care Physicians. American family physician 2018; 97:581-588. http://www.ncbi.nlm.nih.gov/pubmed/?term=29763267

Registry data

  1. Policardo L, Seghieri G, Gualdani E, Franconi F. Effect of statins in preventing hospitalizations for infections: A population study. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29808503
  2. Bartlett LE, Pratt NL, Roughead EE. Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts. Patient preference and adherence 2018; 12:835-843. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805251
  3. Song PS, Ryu DR, Kim MJ et al. Risk Scoring System to Assess Outcomes in Patients Treated with Contemporary Guideline-Adherent Optimal Therapies after Acute Myocardial Infarction. Korean Circ J 2018; 48:492-504. http://www.ncbi.nlm.nih.gov/pubmed/?term=29856143
  4. Klarin D, Cambria RP, Ergul EA et al. Risk factor profile and anatomic features of previously asymptomatic patients presenting with carotid-related stroke. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804741
  5. Lamprecht DG, Jr., Shaw PB, King JB et al. Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29803357
  6. Burkholder GA, Muntner P, Zhao H et al. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853312
  7. Nichols GA, Philip S, Reynolds K et al. Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850861
  8. Zhang X, Jing J, Zhao X et al. Statin Use during Hospitalization and Short-Term Mortality in Acute Ischaemic Stroke with Chronic Kidney Disease. European neurology 2018; 79:296-302. http://www.ncbi.nlm.nih.gov/pubmed/?term=29852478
  9. Jaspers NEM, Visseren FLJ, Numans ME et al. Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives. BMJ Open 2018; 8:e021309. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804065
  10. Tran PT, Meeker AK, Platz EA. Association between statin drug use and peripheral blood leukocyte telomere length in the National Health and Nutrition Examination Survey 1999-2002: a cross-sectional study. Annals of epidemiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29853162
  11. Corsini A, Pacini D, Lovato L et al. Long-term Follow up of Patients with Acute Aortic Syndromes: Relevance of both Aortic and Non-aortic Events. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779910
  12. Oh TK, Kim K, Jheon S et al. Impact of Statin Use on Recurrence or Survival After Surgical Curative Resection of Non-Small Cell Lung Cancer. Cancer control : journal of the Moffitt Cancer Center 2018; 25:1073274818778000. http://www.ncbi.nlm.nih.gov/pubmed/?term=29781295
  13. Lin J, Banathy A, Winters C et al. Achieving Guideline-Driven High-Intensity Statin Dose in Cardiac Rehabilitation Patients With Coronary Artery Disease. Journal of cardiopulmonary rehabilitation and prevention 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29762264
  14. Mechtouff L, Haesebaert J, Viprey M et al. Secondary Prevention Three and Six Years after Stroke Using the French National Insurance Healthcare System Database. European neurology 2018; 79:272-280. http://www.ncbi.nlm.nih.gov/pubmed/?term=29758555
  15. Lindbohm J, Korja M, Jousilahti P et al. Adverse lipid profile elevates risk for subarachnoid hemorrhage: A prospective population-based cohort study. Atherosclerosis 2018; 274:112-119. http://www.ncbi.nlm.nih.gov/pubmed/?term=29772479
  16. Thiney M, Della Schiava N, Ecochard R et al. Effects on mortality and cardiovascular events of adherence to guideline-recommended therapy 4 years after lower extremity arterial revascularization. Annals of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29777848
  17. Park JS, Kim BW, Hong TJ et al. Lower In-Hospital Ventricular Tachyarrhythmia in Patients With Acute Myocardial Infarction Receiving Prior Statin Therapy. Angiology 2018:3319718775902. http://www.ncbi.nlm.nih.gov/pubmed/?term=29758993
  18. Booth JN, 3rd, Colantonio LD, Rosenson RS et al. Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29739799
  19. Nanna MG, Navar AM, Wang TY et al. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29739801
  20. Kim YS, Park MS, Lee JH et al. Effect of Statins on Survival Following Stroke in Patients With Cancer. Frontiers in neurology 2018; 9:205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29740381
  21. Kim S, Kim H, Kim E et al. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-Based Study in South Korea. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735297
  22. Virani SS, Kennedy KF, Akeroyd JM et al. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol >/=190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes 2018; 11:e004652. http://www.ncbi.nlm.nih.gov/pubmed/?term=29748356
  23. Nakamura Y, Asaumi Y, Miyagi T et al. Comparison of Long-Term Mortality in Patients With Previous Coronary Artery Bypass Grafting Who Underwent Percutaneous Coronary Intervention With Versus Without Optimal Medical Therapy. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29747859
  24. Allott EH, Farnan L, Steck SE et al. Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC. Prostate 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29717502
  25. Lin TK, Chou P, Lin CH et al. Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study. PLoS One 2018; 13:e0196713. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723231
  26. Quon J, Parkin L, Sharples K, Barson D. Co-prescribing of contraindicated and use-with-caution drugs in a national cohort of new users of simvastatin: how well are prescribing guidelines followed? The New Zealand medical journal 2018; 131:35-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723177
  27. Kim BS, Yang JH, Jang WJ et al. Long-term Survival Benefit of Statin in Patients with Coronary Chronic Total Occlusion without Revascularization. J Korean Med Sci 2018; 33:e134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29713254
  28. Leppien E, Mulcahy K, Demler TL et al. Effects of Statins and Cholesterol on Patient Aggression: Is There a Connection? Innovations in clinical neuroscience 2018; 15:24-27. http://www.ncbi.nlm.nih.gov/pubmed/?term=29707423
  29. Lin HW, Ho YF, Lin FJ. Statin Use Associated with Lower Risk of Epilepsy after Intracranial Hemorrhage: A Population-Based Cohort Study. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29714813

Renal Disease

  1. Zhang X, Jing J, Zhao X et al. Statin Use during Hospitalization and Short-Term Mortality in Acute Ischaemic Stroke with Chronic Kidney Disease. European neurology 2018; 79:296-302. http://www.ncbi.nlm.nih.gov/pubmed/?term=29852478
  2. Zou R, Shi W, Tao J et al. Efficacy of Statin Therapy Related to Baseline Renal Function in Patients with Rheumatic Heart Disease Undergoing Cardiac Surgery. BioMed research international 2018; 2018:5972064. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850539

Reviews

  1. Andrade Lopes S, Fumani C, Jornayvaz FR et al. [Dyslipidemia management in patients with type 1 diabetes]. Revue medicale suisse 2018; 14:1118-1122. http://www.ncbi.nlm.nih.gov/pubmed/?term=29851318
  2. Bandyopadhyay D, Qureshi A, Ghosh S et al. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management. Journal of lipids 2018; 2018:8598054. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850255
  3. King K, Macken A, Blake O, O'Gorman CS. Cholesterol screening and statin use in children: a literature review. Irish journal of medical science 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29858795
  4. Rocha KCE, Pereira BMV, Rodrigues AC. An update on efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29842801
  5. Mosepele M, Molefe-Baikai OJ, Grinspoon SK, Triant VA. Benefits and Risks of Statin Therapy in the HIV-Infected Population. Current infectious disease reports 2018; 20:20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804227
  6. Devereaux PJ. Suboptimal Outcome of Myocardial Infarction After Noncardiac Surgery: Physicians Can and Should Do More. Circulation 2018; 137:2340-2343. http://www.ncbi.nlm.nih.gov/pubmed/?term=29844070
  7. Maksymets T, Karpyshyn N, Gutor T et al. Influence of risk factors on insulin resistance in patients with overweight and obesity. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2018; 71:558-560. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783224
  8. Carvalho AAS, da Silva VG, Zanoteli E, Feder D. Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report. Therapeutics and clinical risk management 2018; 14:903-907. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785116
  9. Auer J, Berent R. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Ther Adv Cardiovasc Dis 2018:1753944718775352. http://www.ncbi.nlm.nih.gov/pubmed/?term=29792380
  10. Maillart E. Treatment of progressive multiple sclerosis: Challenges and promising perspectives. Revue neurologique 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779852
  11. Wilke RA. Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection. Personalized medicine 2006; 3:385-390. http://www.ncbi.nlm.nih.gov/pubmed/?term=29788593
  12. Molokhia M, Bhatia S, Nitsch D. Genetic determinants of statin-associated myopathy. Personalized medicine 2008; 5:481-494. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783452
  13. Nguyen KA, Li L, Lu D et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785580
  14. Agarwala A, Kulkarni S, Maddox T. The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. Current cardiology reports 2018; 20:50. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779165
  15. Holl DC, Volovici V, Dirven CMF et al. Pathophysiology and non-surgical treatment of chronic subdural hematoma: from past to present to future. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29772364
  16. Andrews J, Psaltis PJ, Bartolo BAD et al. Coronary arterial calcification: A review of mechanisms, promoters and imaging. Trends Cardiovasc Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29753636
  17. Bandyopadhyay D, Ashish K, Hajra A et al. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. Journal of lipids 2018; 2018:3179201. http://www.ncbi.nlm.nih.gov/pubmed/?term=29770231
  18. Simonson W. Update on statin drugs for lipid disorders. Geriatric nursing (New York, N.Y.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29776686
  19. Awad K, Banach M. The optimal time of day for statin administration: a review of current evidence. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29771699
  20. Ayers J, Cook J, Koenig RA et al. Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review. Curr Atheroscler Rep 2018; 20:29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29766349
  21. Lin XL, Xiao LL, Tang ZH et al. Role of PCSK9 in lipid metabolism and atherosclerosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 104:36-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29758414
  22. Vos E, Biron P. Strokes, cholesterol and statins: When mortality is an endpoint. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29764697
  23. Roberts WC. Quantitative Extent of Atherosclerotic Plaque in the Major Epicardial Coronary Arteries in Patients with Fatal Coronary Heart Disease, in Coronary Endarterectomy Specimens, in Aorta-Coronary Saphenous Venous Conduits, and Means to Prevent the Plaques: A Review after Studying the Coronary Arteries for 50 Years. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29753395
  24. Ebell MH, Grad R. Top 20 Research Studies of 2017 for Primary Care Physicians. American family physician 2018; 97:581-588. http://www.ncbi.nlm.nih.gov/pubmed/?term=29763267
  25. Teramoto T. Extending the "Lower is Better" Principle to Japanese and Possibly Other Asian Populations. Circulation 2018; 137:2010-2012. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735588
  26. Ross S, Gerstein H, Pare G. The Genetic Link Between Diabetes and Atherosclerosis. Can J Cardiol 2018; 34:565-574. http://www.ncbi.nlm.nih.gov/pubmed/?term=29731020
  27. Mach F, Ray KK, Wiklund O et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29718253

Safety and side effects

  1. Mosepele M, Molefe-Baikai OJ, Grinspoon SK, Triant VA. Benefits and Risks of Statin Therapy in the HIV-Infected Population. Current infectious disease reports 2018; 20:20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804227
  2. Kim W, Yoon YE, Shin SH et al. Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29857919
  3. Hjelmesaeth J, Asberg A, Andersson S et al. Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). BMJ Open 2018; 8:e021878. http://www.ncbi.nlm.nih.gov/pubmed/?term=29844102
  4. Delluc A, Lacut K, Pan-Petesch B et al. Statin exposure and thrombosis risk in patients with myeloproliferative neoplasms. Thrombosis research 2018; 167:57-59. http://www.ncbi.nlm.nih.gov/pubmed/?term=29787944
  5. Carvalho AAS, da Silva VG, Zanoteli E, Feder D. Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report. Therapeutics and clinical risk management 2018; 14:903-907. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785116
  6. Wilke RA. Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection. Personalized medicine 2006; 3:385-390. http://www.ncbi.nlm.nih.gov/pubmed/?term=29788593
  7. Molokhia M, Bhatia S, Nitsch D. Genetic determinants of statin-associated myopathy. Personalized medicine 2008; 5:481-494. http://www.ncbi.nlm.nih.gov/pubmed/?term=29783452
  8. Dalugama C, Pathirage M, Kularatne SAM. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. Journal of medical case reports 2018; 12:143. http://www.ncbi.nlm.nih.gov/pubmed/?term=29784023
  9. Leite GAA, Figueiredo TM, Guerra MT et al. Ascorbic acid co-administered with rosuvastatin reduces reproductive impairment in the male offspring from male rats exposed to the statin at pre-puberty. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29778496
  10. Nguyen KA, Li L, Lu D et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29785580
  11. Agarwala A, Kulkarni S, Maddox T. The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. Current cardiology reports 2018; 20:50. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779165
  12. Dawra VK, Cutler DL, Zhou S et al. Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects. Clinical pharmacology in drug development 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29786959
  13. Chang JH, Zhang X, Messick K et al. Unremarkable Impact of Oatp Inhibition on the Liver Concentration of Fluvastatin, Lovastatin and Pitavastatin in Wild-Type and Oatp1a/1b Knockout Mouse. Xenobiotica 2018:1-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=29768081
  14. Li H, Lin H, Zhao H et al. Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People's Republic of China. Therapeutics and clinical risk management 2018; 14:823-832. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765224
  15. Ihle P, Dippel FW, Schubert I. Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany. Pharmacol Res Perspect 2018; 6:e00404. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760929
  16. Cai L, Bai X, Lei H et al. High Plasma Exposure of Statins Associated With Increased Risk of Contrast-Induced Acute Kidney Injury in Chinese Patients With Coronary Artery Disease. Frontiers in pharmacology 2018; 9:427. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760658
  17. Emad M, Arjmand H, Farpour HR, Kardeh B. Lipid-lowering drugs (statins) and peripheral neuropathy. Electronic physician 2018; 10:6527-6533. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765578
  18. Ayers J, Cook J, Koenig RA et al. Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review. Curr Atheroscler Rep 2018; 20:29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29766349
  19. Zhou ZY, Huang B, Li S et al. Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish. Toxicology and applied pharmacology 2018; 350:32-42. http://www.ncbi.nlm.nih.gov/pubmed/?term=29730311
  20. Carson RA, Rudine AC, Tally SJ et al. Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms. PLoS One 2018; 13:e0196387. http://www.ncbi.nlm.nih.gov/pubmed/?term=29738536
  21. Chen X, Wang S, Lin L et al. Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis. Pak J Pharm Sci 2018; 31:1169-1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29737302
  22. Nanna MG, Navar AM, Wang TY et al. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29739801
  23. Ross S, Gerstein H, Pare G. The Genetic Link Between Diabetes and Atherosclerosis. Can J Cardiol 2018; 34:565-574. http://www.ncbi.nlm.nih.gov/pubmed/?term=29731020
  24. Kirhmajer MV, Sarinic VM, Simicevic L et al. Rosuvastatin-induced rhabdomyolysis - Possible role of ticagrelor and patients' Pharmacogenetic profile. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29734517
  25. Allott EH, Farnan L, Steck SE et al. Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC. Prostate 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29717502
  26. Kaleem Z, Khan JA, Mushtaq Z et al. Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. Pak J Pharm Sci 2018; 31:801-806. http://www.ncbi.nlm.nih.gov/pubmed/?term=29716858
  27. Quon J, Parkin L, Sharples K, Barson D. Co-prescribing of contraindicated and use-with-caution drugs in a national cohort of new users of simvastatin: how well are prescribing guidelines followed? The New Zealand medical journal 2018; 131:35-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723177
  28. Bae SH, Park WS, Han S et al. Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2018; 22:321-329. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719454
  29. Yamazaki S. Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters. Journal of clinical pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723430
  30. Leppien E, Mulcahy K, Demler TL et al. Effects of Statins and Cholesterol on Patient Aggression: Is There a Connection? Innovations in clinical neuroscience 2018; 15:24-27. http://www.ncbi.nlm.nih.gov/pubmed/?term=29707423
  31. Kubo Y, Akanuma SI, Hosoya KI. Recent advances in drug and nutrient transport across the blood-retinal barrier. Expert Opin Drug Metab Toxicol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719158
  32. Mach F, Ray KK, Wiklund O et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29718253
  33. Yao Y, Toshimoto K, Kim SJ et al. Quantitative analysis of complex drug-drug interactions (DDIs) between cerivastatin and inhibitors using physiologically based pharmacokinetic (PBPK) modeling. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29712725
  34. de Bruyn T, Ufuk A, Cantrill C et al. Predicting Human Clearance of OATP substrates using Cynomolgus monkey: In vitro-in vivo scaling of hepatic uptake clearance. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29720472
  35. Benesic A, Rotter I, Dragoi D et al. Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-induced Liver Injury. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723689
  36. Ayesha SM, Meena AK, Vangala N et al. Necrotizing Autoimmune Myopathy: Clinicopathologic Study from a Single Tertiary Care Centre. Annals of Indian Academy of Neurology 2018; 21:62-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29720800

Stroke and CNS

  1. Texakalidis P, Giannopoulos S, Kokkinidis DG et al. Outcome of Carotid Artery Endarterectomy in Statin-users versus Statin-naive patients: A Systematic Review and Meta-analysis. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29859356
  2. Uransilp N, Chaiyawatthanananthn P, Muengtaweepongsa S. Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial. Neurology research international 2018; 2018:7268924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850244
  3. Han J, Yin QH, Fang Y et al. Atorvastatin protects BV2 mouse microglia and hippocampal neurons against oxygenglucose deprivationinduced neuronal inflammatory injury by suppressing the TLR4/TRAF6/NFkappaB pathway. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29845194
  4. Spanos K, Tzorbatzoglou I, Lazari P et al. Carotid artery plaque echomorphology and its association with histopathologic characteristics. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29803682
  5. Klarin D, Cambria RP, Ergul EA et al. Risk factor profile and anatomic features of previously asymptomatic patients presenting with carotid-related stroke. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804741
  6. Zhang X, Jing J, Zhao X et al. Statin Use during Hospitalization and Short-Term Mortality in Acute Ischaemic Stroke with Chronic Kidney Disease. European neurology 2018; 79:296-302. http://www.ncbi.nlm.nih.gov/pubmed/?term=29852478
  7. Maillart E. Treatment of progressive multiple sclerosis: Challenges and promising perspectives. Revue neurologique 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29779852
  8. Konishi T, Funayama N, Yamamoto T et al. Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29789903
  9. Harewood-Marshall AS, Craig LS, Martelly TP et al. Managing acute ischaemic stroke in a small island developing state: meeting the guidelines in Barbados. BMC public health 2018; 18:648. http://www.ncbi.nlm.nih.gov/pubmed/?term=29788951
  10. Holl DC, Volovici V, Dirven CMF et al. Pathophysiology and non-surgical treatment of chronic subdural hematoma: from past to present to future. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29772364
  11. Mechtouff L, Haesebaert J, Viprey M et al. Secondary Prevention Three and Six Years after Stroke Using the French National Insurance Healthcare System Database. European neurology 2018; 79:272-280. http://www.ncbi.nlm.nih.gov/pubmed/?term=29758555
  12. Lindbohm J, Korja M, Jousilahti P et al. Adverse lipid profile elevates risk for subarachnoid hemorrhage: A prospective population-based cohort study. Atherosclerosis 2018; 274:112-119. http://www.ncbi.nlm.nih.gov/pubmed/?term=29772479
  13. Chen X, Wang S, Lin L et al. Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis. Pak J Pharm Sci 2018; 31:1169-1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29737302
  14. Kim YS, Park MS, Lee JH et al. Effect of Statins on Survival Following Stroke in Patients With Cancer. Frontiers in neurology 2018; 9:205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29740381
  15. Zheng W, Yang W, Zhang QE et al. Meta-analysis of the Efficacy and Safety of Adjunctive Rosuvastatin for Dyslipidemia in Patients with Schizophrenia. Shanghai archives of psychiatry 2018; 30:4-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719353
  16. Jin Z, Jung Y, Yi CO et al. Atorvastatin pretreatment attenuates kainic acid-induced hippocampal neuronal death via regulation of lipocalin-2-associated neuroinflammation. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2018; 22:301-309. http://www.ncbi.nlm.nih.gov/pubmed/?term=29719452
  17. Leppien E, Mulcahy K, Demler TL et al. Effects of Statins and Cholesterol on Patient Aggression: Is There a Connection? Innovations in clinical neuroscience 2018; 15:24-27. http://www.ncbi.nlm.nih.gov/pubmed/?term=29707423
  18. Minhas JS, Wang X, Arima H et al. Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Cerebrovasc Dis 2018; 45:213-220. http://www.ncbi.nlm.nih.gov/pubmed/?term=29705803
  19. Lin HW, Ho YF, Lin FJ. Statin Use Associated with Lower Risk of Epilepsy after Intracranial Hemorrhage: A Population-Based Cohort Study. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29714813

Triglycerides/HDL

  1. Nichols GA, Philip S, Reynolds K et al. Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850861
  2. Colombo M, Looker HC, Farran B et al. Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis 2018; 274:182-190. http://www.ncbi.nlm.nih.gov/pubmed/?term=29793175
  3. Cartolano FC, Pappiani C, Freitas MCP et al. Is Lipid Accumulation Product Associated with an Atherogenic Lipoprotein Profile in Brazilian Subjects? Arquivos brasileiros de cardiologia 2018; 110:339-347. http://www.ncbi.nlm.nih.gov/pubmed/?term=29791572
  4. Zheng D, Cai A, Xu R et al. Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia. Archives of medical science : AMS 2018; 14:629-634. http://www.ncbi.nlm.nih.gov/pubmed/?term=29765452
  5. Yang Y, Wang J, He H et al. Influence of Fatty Acid Modification on Uptake of Lovastatin-Loaded Reconstituted High Density Lipoprotein by Foam Cells. Pharm Res 2018; 35:134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29736804

Trials

  1. Li Y, Zhao SP, Li Y. [Periprocedural high-dose statin strategy shown no benefits on clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary interventions]. Zhonghua xin xue guan bing za zhi 2018; 46:338-340. http://www.ncbi.nlm.nih.gov/pubmed/?term=29804433
  2. Uransilp N, Chaiyawatthanananthn P, Muengtaweepongsa S. Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial. Neurology research international 2018; 2018:7268924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29850244
  3. Jiang LY, Jiang YH, Qi YZ et al. Integrated analysis of long noncoding RNA and mRNA profiling ox-LDL-induced endothelial dysfunction after atorvastatin administration. Medicine (Baltimore) 2018; 97:e10949. http://www.ncbi.nlm.nih.gov/pubmed/?term=29851839
  4. Spanos K, Tzorbatzoglou I, Lazari P et al. Carotid artery plaque echomorphology and its association with histopathologic characteristics. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29803682
  5. Degala S, Bathija NA. Evaluation of the Efficacy of Simvastatin in Bone Regeneration after Surgical Removal of Bilaterally Impacted Third Molars-A Split-Mouth Randomized Clinical Trial. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29859160
  6. Liu C, Liu Q, Xiao X. Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease. Experimental and therapeutic medicine 2018; 15:4683-4688. http://www.ncbi.nlm.nih.gov/pubmed/?term=29805487
  7. Ageev FT, Blankova ZN, Samsonova NS. [The effect of changing of conventional antihypertensive therapy to a triple fixed combination therapy with rosuvastatin in high cardiovascular risk patients]. Kardiologiia 2018:46-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=29782289
  8. Konishi T, Funayama N, Yamamoto T et al. Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29789903
  9. Oh M, Ghim JL, Park SE et al. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects. Drug design, development and therapy 2018; 12:1157-1164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29780236
  10. Ju A, Hanson CS, Banks E et al. Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29784867
  11. Colombo M, Looker HC, Farran B et al. Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis 2018; 274:182-190. http://www.ncbi.nlm.nih.gov/pubmed/?term=29793175
  12. Cai L, Bai X, Lei H et al. High Plasma Exposure of Statins Associated With Increased Risk of Contrast-Induced Acute Kidney Injury in Chinese Patients With Coronary Artery Disease. Frontiers in pharmacology 2018; 9:427. http://www.ncbi.nlm.nih.gov/pubmed/?term=29760658
  13. Chen X, Wang S, Lin L et al. Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis. Pak J Pharm Sci 2018; 31:1169-1173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29737302
  14. Piechota-Polanczyk A, Kopacz A, Kloska D et al. Simvastatin Treatment Upregulates HO-1 in Patients with Abdominal Aortic Aneurysm but Independently of Nrf2. Oxidative medicine and cellular longevity 2018; 2018:2028936. http://www.ncbi.nlm.nih.gov/pubmed/?term=29743974
  15. Gordon JA, Buonerba C, Pond G et al. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget 2018; 9:19861-19873. http://www.ncbi.nlm.nih.gov/pubmed/?term=29731989
  16. Elbadawi-Sidhu M, Baillie RA, Zhu H et al. Pharmacometabolomic signature links simvastatin therapy and insulin resistance. Metabolomics : open access 2017; 13. http://www.ncbi.nlm.nih.gov/pubmed/?term=29732238
  17. Basyoni MMA, Fouad SA, Amer MF et al. Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy. The Korean journal of parasitology 2018; 56:105-112. http://www.ncbi.nlm.nih.gov/pubmed/?term=29742864
  18. Cano-Corres R, Candas-Estebanez B, Padro-Miquel A et al. Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia. Journal of clinical laboratory analysis 2018:e22566. http://www.ncbi.nlm.nih.gov/pubmed/?term=29732606
  19. Fujisue K, Shirakawa T, Nakamura S et al. Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases - INVITATION trial. J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735336
  20. Balaguer C, Peralta A, Rios A et al. Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. Contemporary clinical trials communications 2016; 2:91-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=29736450
  21. Hesami O, Sistanizad M, Asadollahzade E et al. Comparing the Effects of Atorvastatin With Sodium Valproate (Divalproex) on Frequency and Intensity of Frequent Migraine Headaches: A Double-blind Randomized Controlled Study. Clinical neuropharmacology 2018; 41:94-97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29746282
  22. Brinton EA. Understanding Patient Adherence and Concerns with STatins and MedicatION Discussions with Physicians (ACTION): A Survey on the Patient Perspective of Dialogue with Healthcare Providers Regarding Statin Therapy. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29749101
  23. Ray KK, Stoekenbroek RM, Kallend D et al. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735484
  24. Taguchi I, Iimuro S, Iwata H et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation 2018; 137:1997-2009. http://www.ncbi.nlm.nih.gov/pubmed/?term=29735587
  25. Clarke R, Valdes-Marquez E, Hill M et al. Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. Open heart 2018; 5:e000807. http://www.ncbi.nlm.nih.gov/pubmed/?term=29713486
  26. Elwan N, Salah R, Hamisa M et al. Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial. F1000Research 2018; 7:256. http://www.ncbi.nlm.nih.gov/pubmed/?term=29707200
  27. Benesic A, Rotter I, Dragoi D et al. Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-induced Liver Injury. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29723689
  28. Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual Inflammatory Risk On Treatment with PCSK9 Inhibition and Statin Therapy. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29716940
  29. Minhas JS, Wang X, Arima H et al. Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Cerebrovasc Dis 2018; 45:213-220. http://www.ncbi.nlm.nih.gov/pubmed/?term=29705803
  30. Karlson BW, Nicholls SJ, Lundman P et al. Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. Cardiology 2018; 140:30-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=29705799

Women and elderly

  1. Ofori-Asenso R, Ilomaki J, Zomer E et al. A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29790056
  2. Moreno-Arellano S, Delgado-de-Mendoza J, Santi-Cano MJ. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men. Nutrition, metabolism, and cardiovascular diseases : NMCD 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29754716
  3. Alter DA, Tu JV, Koh M et al. Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29754125
  4. Kuller LH. Reducing Low-Density Lipoprotein Cholesterol After Myocardial Infarction in Older Individuals, Levels Versus Change: Can Observational Studies Answer the Questions? J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29754126
  5. Nanna MG, Navar AM, Wang TY et al. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29739801

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.